What is Lunaphore Technologies?
Headquartered in Switzerland, Lunaphore Technologies specializes in the development of next-generation tissue autostainers. The company is fundamentally transforming in-situ tissue analytics by integrating high-throughput, automated processes that mirror omic-level precision. This technological advancement is critical for cancer research and clinical diagnostics, where the ability to analyze tissue samples with high spatial resolution and speed is paramount. By bridging the gap between traditional histology and advanced molecular diagnostics, Lunaphore provides researchers and clinicians with the tools necessary to unlock deeper biological insights, thereby facilitating more personalized and effective therapeutic interventions.
How much funding has Lunaphore Technologies raised?
Lunaphore Technologies has raised a total of $92.9M across 7 funding rounds:
Series A
$2.1M
Private Equity
$6.1M
Series B
$5.3M
Series C
$23.6M
Other Financing Round
$2.1M
Debt
$10M
Series D
$43.7M
Series A (2015): $2.1M with participation from Redalpine Venture Partners
Private Equity (2017): $6.1M led by Polytech Ecosystem Ventures, Zu00fchlke Ventures, Redalpine Venture Partners, and Occident
Series B (2018): $5.3M supported by Occident and Zürcher Kantonalbank
Series C (2020): $23.6M featuring PHC Holdings Corporation, Redalpine Venture Partners, Alpana Ventures, and OCCIDENT
Other Financing Round (2020): $2.1M backed by Swiss Entrepreneurs Fund
Debt (2022): $10M with participation from Norgine Ventures Management
Series D (2023): $43.7M led by Ernst Göhner, Redalpine, and PHC Group
Key Investors in Lunaphore Technologies
Redalpine Venture Partners
A thesis-driven venture capital firm established in 2006 that leverages a unique team of scientists and operators to support highly technical companies in the software and science sectors.
Occident
An international, owner-managed venture capital investor focusing on deep tech start-ups within the life sciences and high-tech sectors across Germany and Switzerland.
PHC Group
A global healthcare company specializing in diagnostic services and medical technologies, providing comprehensive solutions to healthcare facilities across Asia, Europe, and North America.
What's next for Lunaphore Technologies?
With the recent influx of capital, Lunaphore Technologies is well-positioned to accelerate its commercial expansion and deepen its R&D capabilities. The strategic focus will likely shift toward scaling the global distribution of its diagnostic platforms and enhancing the software ecosystem that supports its hardware. As the company matures, it is expected to leverage its strong investor network—which includes both specialized venture capital firms and global healthcare conglomerates—to navigate regulatory landscapes and penetrate key international markets. The ongoing commitment to innovation suggests that Lunaphore will continue to play a pivotal role in the evolution of precision medicine, potentially setting new benchmarks for diagnostic efficiency and analytical depth in the oncology space.
See full Lunaphore Technologies company page
